Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
Director departure
CC transcript
ALBIREO PHARMA, INC. (ALBO) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/02/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Article 6:",
"SECOND AMENDED AND RESTATED BYLAWS OF ALBIREO PHARMA, INC. Article 1: Corporate Offices Section 1.1 Offices . In addition to the corporation’ s registered office set forth in the certificate of incorporation, the Board of Directors may at any time establish other offices at any place or places where the corporation is qualified to do business. Article 2: Meetings of Stockholders Section 2.1 Place of Meetings . Meetings of stockholders may be held at any place, either within or without the state of Delaware, as may be designated by the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211 of the Delaware Gener..."
02/14/2023 8-K Quarterly results
01/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Agreement and Plan of Merger, by and among Ipsen Biopharmaceuticals, Inc., Anemone Acquisition Corp., Albireo Pharma, Inc. and, solely for the limited purposes set forth therein, Ipsen Pharma SAS",
"Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases"
12/06/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Albireo Reports Q3 2022 Financial Results and Business Update"
10/11/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay in Alagille Syndrome",
"4 POSITIVE TOPLINE DATA RESULTS"
09/22/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Albireo Announces $115 Million Royalty Monetization Agreement with Sagard"
08/15/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
08/15/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
07/29/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
06/17/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
01/05/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Albireo Increases 2021 Bylvay TM Sales Guidance"
12/09/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Albireo Reports Q3 Financial Results and Business Update"
09/07/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Albireo Sells Priority Review Voucher for $105 Million"
08/05/2021 8-K Quarterly results
07/20/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Albireo Receives European Marketing Authorization of Bylvay™ , the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis",
"Albireo Announces FDA Approval of Bylvay™ , the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis"
06/21/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/25/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat"
12/08/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC"
11/13/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease"
11/05/2020 8-K Quarterly results
Docs: "Albireo Pharma, Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2020 2019 Assets Current assets: Cash and cash equivalents $ 278,691 $ 131,843 Prepaid expenses and other current assets 8,199 9,956 Total current assets 286,890 141,799 Property and equipment, net 551 597 Goodwill 17,260 17,260 Other assets 6,401 5,413 Total assets $ 311,102 $ 165,069 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,601 $ 4,785 Accrued expenses 16,817 13,486 Other current liabilities 810 653 Total current liabilities 21,228 18,924 Liability related to sale of future royalties 64,871 48,714 Note payable, net of discount 9,508 — Other long-term liabilities 3,735 4,270 Total liabilities 99,342 71,908 Stockholders’ Equity: Common stock, $0.01 par value per shar..."
10/15/2020 8-K Quarterly results
09/10/2020 8-K Quarterly results
09/09/2020 8-K Quarterly results
09/08/2020 8-K Quarterly results
09/08/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy